---
document_datetime: 2025-12-01 10:54:11
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/akynzeo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: akynzeo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.3838323
conversion_datetime: 2025-12-24 14:32:41.855042
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Akynzeo

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Article 61(3) /      | - Notification acc. Article 61(3) - Accepted | 28/11/2025                          |                                             | PL                               |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/N/0000314740                      | Update of package leaflet with revised contact details of local representatives.                                                                                                                                                                                                                                                                                             |            |     |                   |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------|
| Variation type IA / EMA/VR/0000313866 | B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted                                                                                                                                                                                                                                               | 25/11/2025 | N/A |                   |
| Variation type IA /                   | A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted                                                                                                        | 20/10/2025 | N/A | EMA/VR/0000307062 |
| Variation type IB / EMA/VR/0000278852 | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.z Other variation - Accepted | 28/08/2025 | N/A |                   |
| Variation type IB / EMA/VR/0000278800 | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control                                                                                                                                                             | 03/07/2025 | N/A |                   |

<div style=\"page-break-after: always\"></div>

|                                       | testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                |            |     |                                                                                                                                                                                                                                                                       |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUR / EMA/PSUR/0000248514            | - -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 05/06/2025 |     | Based on the PRAC review of data on safety and efficacy, the PRAC considers that the risk-benefit balance of medicinal products containing (fos)netupitant/palonosetron remains unchanged and therefore recommends the maintenance of the marketing authorisation(s). |
| Variation type IA / EMA/VR/0000246144 | This was an application for a group of variations. B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.a Replacement or addition of a site where batch control/testing takes place - Accepted B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.a Replacement or addition of a site where batch control/testing takes place - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the | 24/01/2025 | N/A |                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.III.1.b European Pharmacopoeial TSE Certificate of suitability for an active substance/starting material/reagent/ intermediate/or excipient - B.III.1.b.3 Updated certificate from an already approved manufacturer - Accepted   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|